Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Common Equity (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Common Equity for 6 consecutive years, with $33.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 55.93% to $33.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.2 million through Dec 2025, down 55.93% year-over-year, with the annual reading at $33.2 million for FY2025, 55.93% down from the prior year.
  • Common Equity hit $33.2 million in Q4 2025 for Rapid Micro Biosystems, down from $44.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $234.7 million in Q3 2021 to a low of -$164.5 million in Q2 2021.
  • Historically, Common Equity has averaged $99.1 million across 5 years, with a median of $112.0 million in 2023.
  • Biggest YoY gain for Common Equity was 306.25% in 2021; the steepest drop was 59.38% in 2021.
  • Year by year, Common Equity stood at $221.0 million in 2021, then decreased by 25.71% to $164.2 million in 2022, then fell by 28.13% to $118.0 million in 2023, then tumbled by 36.14% to $75.4 million in 2024, then crashed by 55.93% to $33.2 million in 2025.
  • Business Quant data shows Common Equity for RPID at $33.2 million in Q4 2025, $44.3 million in Q3 2025, and $54.5 million in Q2 2025.